-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15

Benzinga·10/22/2026 10:44:04
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $15.